Pardaphash Ads
  1. Home
  2. Health
  3. AstraZeneca Withdraws COVID-19 Vaccine Globally

AstraZeneca Withdraws COVID-19 Vaccine Globally

AstraZeneca has initiated the global withdrawal of its COVID-19 vaccine, Vaxzevria, citing a surplus of more advanced vaccine options targeting emerging variants of the virus.

By: Team Pardaphash  Pardaphash Group
AstraZeneca Withdraws COVID-19 Vaccine Globally

AstraZeneca’s decision, announced on Tuesday, underscores a shift in demand towards more advanced vaccine options. With multiple variant-specific vaccines now available, the company cited a surplus of updated alternatives as a contributing factor to the waning demand for Vaxzevria. Consequently, AstraZeneca intends to revoke the marketing authorizations for the vaccine across Europe.

Acknowledgement of Rare Side Effects

In a notable admission, AstraZeneca has acknowledged the potential for rare side effects associated with its COVID-19 vaccine, specifically the occurrence of thrombosis with thrombocytopenia syndrome (TTS) in very rare cases. This condition, characterized by the formation of blood clots alongside reduced platelet levels, has prompted heightened scrutiny. AstraZeneca clarified that the causal mechanism behind TTS remains unclear and emphasized that such events can occur independently of vaccination.

Contradictory Stance Over Time

The acknowledgment of rare side effects marks a notable departure from AstraZeneca’s earlier position, contradicting its previous denial of a widespread link between the vaccine and TTS in 2023. The company’s shifting stance reflects the evolving understanding of vaccine safety and underscores the complexity of assessing causation in individual cases.

Withdrawal Application and Effective Date

AstraZeneca submitted its application to withdraw the vaccine on March 5, and the withdrawal officially took effect on May 7. This move marks a significant development in the ongoing efforts to manage COVID-19 vaccine distribution and address emerging safety concerns.

Diversification Beyond COVID-19

Amid the decline in COVID-19 medicine sales, AstraZeneca has diversified its portfolio, venturing into respiratory syncytial virus vaccines and obesity drugs through strategic partnerships and acquisitions. Notably, the company collaborated with the Serum Institute of India (SII) to supply the vaccine to the Indian Government .

Further reading:
For the latest news and reviews, follow us on Google, Facebook, YouTube and X (Twitter)